Daily Antiretroviral Prophylaxis Reduced Risk of HIV Infection
Major Finding: Taking a daily pill containing the antiretroviral drugs emtricitabine and tenofovir along with using conventional HIV prevention strategies reduced the risk of acquiring HIV by 44% on average in men or transgender women who have sex with men.
Data Source: Randomized, blinded placebo-controlled trial in 2,499 subjects in six countries.
Disclosures: The National Institutes of Health and the Bill and Melinda Gates Foundation funded the study. Gilead Sciences donated the FTC-TDF and placebo tablets, and provided some travel funding for investigators. Two of the investigators worked for Gilead. Disclosures for individual investigators are posted with the article at www.nejm.org. Dr. Das and Dr. Colfax said they have no relevant conflicts of interest.
FROM THE NEW ENGLAND JOURNAL OF MEDICINE
The rate of HIV infection has been climbing since the early 1990s in U.S. men and transgender women who have sex with men, especially in black and Hispanic populations, the investigators in the iPrEx study noted. In almost all countries, the prevalence of HIV is higher among men and transgender women who have sex with men, compared with other groups.
The U.S. National Institutes of Health and the Bill and Melinda Gates Foundation funded the study. Gilead Sciences donated the FTC-TDF and placebo tablets, and provided some travel funding for investigators. Two of the investigators worked for Gilead. Disclosures for all the investigators are posted with the article. Dr. Das and Dr. Colfax said they have no relevant conflicts of interest.
